First Time Loading...
E

Evotec SE
XETRA:EVT

Watchlist Manager
Evotec SE
XETRA:EVT
Watchlist
Price: 9.525 EUR -0.16%
Updated: May 8, 2024

Intrinsic Value

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. [ Read More ]

The intrinsic value of one EVT stock under the Base Case scenario is 23.199 EUR. Compared to the current market price of 9.525 EUR, Evotec SE is Undervalued by 59%.

Key Points:
EVT Intrinsic Value
Base Case
23.199 EUR
Undervaluation 59%
Intrinsic Value
Price
E
Worst Case
Base Case
Best Case

Valuation Backtest
Evotec SE

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling EVT stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Evotec SE

Provide an overview of the primary business activities
of Evotec SE.

What unique competitive advantages
does Evotec SE hold over its rivals?

What risks and challenges
does Evotec SE face in the near future?

Summarize the latest earnings call
of Evotec SE.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Evotec SE.

Provide P/S
for Evotec SE.

Provide P/E
for Evotec SE.

Provide P/OCF
for Evotec SE.

Provide P/FCFE
for Evotec SE.

Provide P/B
for Evotec SE.

Provide EV/S
for Evotec SE.

Provide EV/GP
for Evotec SE.

Provide EV/EBITDA
for Evotec SE.

Provide EV/EBIT
for Evotec SE.

Provide EV/OCF
for Evotec SE.

Provide EV/FCFF
for Evotec SE.

Provide EV/IC
for Evotec SE.

Show me price targets
for Evotec SE made by professional analysts.

What are the Revenue projections
for Evotec SE?

How accurate were the past Revenue estimates
for Evotec SE?

What are the Net Income projections
for Evotec SE?

How accurate were the past Net Income estimates
for Evotec SE?

What are the EPS projections
for Evotec SE?

How accurate were the past EPS estimates
for Evotec SE?

What are the EBIT projections
for Evotec SE?

How accurate were the past EBIT estimates
for Evotec SE?

Compare the revenue forecasts
for Evotec SE with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Evotec SE and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Evotec SE against its competitors.

Analyze the profit margins
(gross, operating, and net) of Evotec SE compared to its peers.

Compare the P/E ratios
of Evotec SE against its peers.

Discuss the investment returns and shareholder value creation
comparing Evotec SE with its peers.

Analyze the financial leverage
of Evotec SE compared to its main competitors.

Show all profitability ratios
for Evotec SE.

Provide ROE
for Evotec SE.

Provide ROA
for Evotec SE.

Provide ROIC
for Evotec SE.

Provide ROCE
for Evotec SE.

Provide Gross Margin
for Evotec SE.

Provide Operating Margin
for Evotec SE.

Provide Net Margin
for Evotec SE.

Provide FCF Margin
for Evotec SE.

Show all solvency ratios
for Evotec SE.

Provide D/E Ratio
for Evotec SE.

Provide D/A Ratio
for Evotec SE.

Provide Interest Coverage Ratio
for Evotec SE.

Provide Altman Z-Score Ratio
for Evotec SE.

Provide Quick Ratio
for Evotec SE.

Provide Current Ratio
for Evotec SE.

Provide Cash Ratio
for Evotec SE.

What is the historical Revenue growth
over the last 5 years for Evotec SE?

What is the historical Net Income growth
over the last 5 years for Evotec SE?

What is the current Free Cash Flow
of Evotec SE?

Discuss the annual earnings per share (EPS)
trend over the past five years for Evotec SE.

Financials

Balance Sheet Decomposition
Evotec SE

Current Assets 903.2m
Cash & Short-Term Investments 616.9m
Receivables 204.1m
Other Current Assets 82.2m
Non-Current Assets 1.3B
Long-Term Investments 142.1m
PP&E 806.6m
Intangibles 291.1m
Other Non-Current Assets 109.6m
Current Liabilities 464.6m
Accounts Payable 134.3m
Other Current Liabilities 330.3m
Non-Current Liabilities 668m
Long-Term Debt 477.1m
Other Non-Current Liabilities 190.9m
Efficiency

Earnings Waterfall
Evotec SE

Revenue
781.4m EUR
Cost of Revenue
-606.4m EUR
Gross Profit
175.1m EUR
Operating Expenses
-217.5m EUR
Operating Income
-42.5m EUR
Other Expenses
-41.4m EUR
Net Income
-83.9m EUR

Free Cash Flow Analysis
Evotec SE

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

EVT Profitability Score
Profitability Due Diligence

Evotec SE's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
Positive Gross Profit
Positive 1-Year Revenue Growth
41/100
Profitability
Score

Evotec SE's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

EVT Solvency Score
Solvency Due Diligence

Evotec SE's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Negative Net Debt
46/100
Solvency
Score

Evotec SE's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EVT Price Targets Summary
Evotec SE

Wall Street analysts forecast EVT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EVT is 25.618 EUR with a low forecast of 10.504 EUR and a high forecast of 52.5 EUR.

Lowest
Price Target
10.504 EUR
10% Upside
Average
Price Target
25.618 EUR
169% Upside
Highest
Price Target
52.5 EUR
451% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

EVT Price
Evotec SE

1M 1M
-34%
6M 6M
-46%
1Y 1Y
-42%
3Y 3Y
-72%
5Y 5Y
-58%
10Y 10Y
+169%
Annual Price Range
9.525
52w Low
9.16
52w High
24.24
Price Metrics
Average Annual Return 1.72%
Standard Deviation of Annual Returns 45.02%
Max Drawdown -80%
Shares Statistics
Market Capitalization 1.7B EUR
Shares Outstanding 176 935 700
Percentage of Shares Shorted
N/A

EVT Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Evotec SE

Country

Germany

Industry

Life Sciences Tools & Services

Market Cap

1.7B EUR

Dividend Yield

0%

Description

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,521 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Contact

HAMBURG
Hamburg
Essener Bogen 7
+4940560810.0
https://www.evotec.com/

IPO

1999-10-11

Employees

4 521

Officers

Interim CEO, Member of the Management Board & Member of the Supervisory Board
Dr. Mario Polywka DPHIL, Ph.D.
Member of Management Board
Dr. Werner Lanthaler M.B.A., MPA, Ph.D.
Chief Scientific Officer & Member of Management Board
Dr. Cord Dohrmann Ph.D.
COO & Member of Management Board
Dr. Craig Johnstone Ph.D.
Chief Business Officer & Member of Management Board
Dr. Matthias Evers Ph.D.
CFO & Member of Management Board
Ms. Laetitia Rouxel
Show More
Principal Accounting Officer and Senior Vice President of Group Accounting
Ms. Anja Bosler
Executive VP and Head of Global Investor Relations & ESG
Mr. Volker Braun
EVP Global Head of Legal & Compliance
Dr. Christian Dargel
Senior VP & Head of Global Corporate Communications & Marketing
Gabriele Hansen
Show Less

See Also

Discover More
What is the Intrinsic Value of one EVT stock?

The intrinsic value of one EVT stock under the Base Case scenario is 23.199 EUR.

Is EVT stock undervalued or overvalued?

Compared to the current market price of 9.525 EUR, Evotec SE is Undervalued by 59%.